Business Wire

CA-EOS-BIOSCIENCES-INC

Del

Eos Biosciences Announces Issuance of Additional U.S. Patent For Targeted Breast Cancer Therapy

Eos Biosciences, Inc. , a bio-targeted nanomedicines company developing a novel nanobiologic particle drug delivery platform technology (Eosomes), and a proprietary oncology-specific product pipeline, announced that the U.S. Patent and Trademark Office has now issued Eos Biosciences a second patent, U.S. Patent No. 9,789,201, for Eos-001 , the company’s HER3-targeted Eosome with doxorubicin payload.

Omar Haffar , Ph.D., Founder, President and Chief Executive Officer, commented, “This is a very exciting time for Eos Biosciences. In addition to expanding and solidifying our patent portfolio, we are making very significant progress on the pre-clinical development and scale-up manufacturing of our products.” Dr. Haffar continued, “We are also implementing a strategic expansion of our product pipeline into immuno-oncology, and the application of Eosomes to other high impact disease areas, such as CNS. We expect to report positive progress in these and other areas in the near future.”

About Eos-001
Eos-001 is a proof-of-concept proprietary product in preclinical development, intended to address Triple Negative Breast Cancer (TNBC) and HER2+ breast cancer resistant or nonresponsive to first line therapies. HER3 is over-expressed on TNBC and many types of HER2+ metastatic and drug-resistant solid tumors.

About Eosomes
Eosomes are innovative self-assembling nanobiologic particles composed of a recombinant polypeptide and a therapeutic payload. The recombinant polypeptide is designed to incorporate three functional domains for cell targeting, active endosomal escape, and therapeutic payload binding. The modular design of the polypeptide provides significant versatility in adapting the application of the Eosomes to multiple disease areas and therapeutic modalities. To date, Eos has generated two forms of Eosomes, one targeting HER3 and one targeting c-Met. Expression of both cell surface receptors is upregulated on metastatic and drug-resistant solid tumors.

About Eos Biosciences, Inc.
Eos Biosciences Inc. is a bio-targeted nanomedicines company based in Los Angeles, California with a worldwide and exclusive license from Cedars-Sinai Medical Center to the intellectual property and know how covering the Eosomes drug-targeting and delivery platform technology.

Contact:

Eos Biosciences, Inc.
Thomas Plotts, +1 424-253-1186
Chief Financial Officer
Thomas.plotts@eosbiosciences.com
www.eosbiosciences.com

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com